JW Life Science acquires commercialization approval of epilepsy therapy ‘Levetiram’

Published: 2017-01-16 13:48:19

Updated: 2017-01-16 13:48:19

A new-concept solution, which relieve seizure for epilepsy patients, will be released in Korea.

JW Life Science(CEO Sung-Nam Cha) announced on the 12^th that it has acquired commercialization approval of ‘Levetiram Inj 1,000mg,’ an epilepsy therapy, from the Ministry of Food and Drug Safety(MFDS).

Levetiram Inj can be used for the first time in Korea as a epilepsy treatment without any dilutin...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.